Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 8269 · CLEAR LABELS Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

19 U.S.C. § 1304 Marking of imported articles and containers

+2 −0Shown
More for 19 U.S.C. § 1304
Read § 1304Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 304 of the Tariff Act of 1930 (19 U.S.C. 1304) is amended by adding at the end the following:(m) Marking of certain finished drug products.— The marking requirements of subsections (a) and (b) shall not apply to articles that are finished drug products and are marked in accordance with the requirements of section 502(b)(3)(A) of the Federal Food, Drug, and Cosmetic Act..

§ 1304(l)–(m)

Start of § 1304 to (l) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(l)(1)(1) (1)
upon conviction for the first violation of this subsection, be fined not more than $100,000, or imprisoned for not more than 1 year, or both; andupon conviction for the first violation of this subsection, be fined not more than $100,000, or imprisoned for not more than 1 year, or both; and
(l)(2)(2) (2)
upon conviction for the second or any subsequent violation of this subsection, be fined not more than $250,000, or imprisoned for not more than 1 year, or both.upon conviction for the second or any subsequent violation of this subsection, be fined not more than $250,000, or imprisoned for not more than 1 year, or both.
(m)(m) [inserted: Marking of certain finished drug products.—]
[inserted: The marking requirements of subsections (a) and (b) shall not apply to articles that are finished drug products and are marked in accordance with the requirements of section 502(b)(3)(A) of the Federal Food, Drug, and Cosmetic Act.]

21 U.S.C. § 352 Misbranded drugs and devices

+27 −2Shown
More for 21 U.S.C. § 352
Read § 352Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 502(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(b)) is amended to read as follows:(b) (1) If it is a finished drug product in a package form, unless it bears a label containing— (A) the name, place of business, and unique facility identifier of the manufacturer, packer, or distributor or a link, barcode, QR code, or other means to access a searchable …

§ 352(a)–(d)

Start of § 352 to (a)(2) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(a)(2)(A)(A) (A)
For purposes of this paragraph,1 the term “health care economic information” means any analysis (including the clinical data, inputs, clinical or other assumptions, methods, results, and other components underlying or comprising the analysis) that identifies, measures, or describes the economic consequences, which may be based on the separate or aggregated clinical consequences of the represented health outcomes, of the use of a drug or device. Such analysis may be comparative to the use of another drug or device, to another health care intervention, or to no intervention.For purposes of this paragraph,1 the term “health care economic information” means any analysis (including the clinical data, inputs, clinical or other assumptions, methods, results, and other components underlying or comprising the analysis) that identifies, measures, or describes the economic consequences, which may be based on the separate or aggregated clinical consequences of the represented health outcomes, of the use of a drug or device. Such analysis may be comparative to the use of another drug or device, to another health care intervention, or to no intervention.
(a)(2)(B)(B) (B)
Such term does not include any analysis that relates only to an indication that is not approved under section 355, 360(k), 360c(f)(2), or 360e of this title or section 262 of title 42 for such drug or device.Such term does not include any analysis that relates only to an indication that is not approved under section 355, 360(k), 360c(f)(2), or 360e of this title or section 262 of title 42 for such drug or device.
(b)(b) [struck: Package form; contents of label](b)
(b)(1)(1) [inserted: ]
[inserted: If it is a finished drug product in a package form, unless it bears a label containing—]
(b)(1)(A)(A) [inserted: ]
[inserted: the name, place of business, and unique facility identifier of the manufacturer, packer, or distributor or a link, barcode, QR code, or other means to access a searchable electronic portal containing such information; and]
(b)(1)(B)(B) [inserted: ]
[inserted: an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count, provided that under this clause reasonable variations shall be permitted, and exemptions as to small packages shall be established, by regulations prescribed by the Secretary.]
(b)(2)(2) [inserted: ]
[inserted: If it is an active pharmaceutical ingredient, unless any accompanying label and certificate of analysis contains the name, place of business, and unique facility identifier of the original manufacturer.]
(b)(3)(3) [inserted: ]
(b)(3)(A)(A) [inserted: ]
[inserted: If it is a finished drug product, unless its labeling contains the name, place of business, and unique facility identifier of—]
(b)(3)(A)(i)(i) [inserted: ]
[inserted: the original manufacturer of each active pharmaceutical ingredient;]
(b)(3)(A)(ii)(ii) [inserted: ]
[inserted: the original manufacturer of the finished drug product; and]
(b)(3)(A)(iii)(iii) [inserted: ]
[inserted: the packer or distributor, if any,]
(b)(3)(A)[inserted: or a link, barcode, QR code, or other means to access a searchable electronic portal containing such information.]
(b)(3)(B)(B) [inserted: ]
[inserted: In the case of a finished drug product for which there are multiple potential different manufacturers of the active pharmaceutical ingredient, the requirements of this subparagraph shall be satisfied if all such manufacturers of active pharmaceutical ingredients for the drug product are identified in the labeling or the searchable electronic portal.]
(b)(4)(4) [inserted: ]
[inserted: A manufacturer, packer, or distributor required to furnish information under subparagraphs (1), (2), and (3), in addition to making such information available electronically, as applicable, shall make such information available through a package insert, or in paper copy to any individual who requests such a copy.]
(b)(5)(5) [inserted: ]
[inserted: For purposes of this paragraph, the term “original manufacturer”, means the single last establishment to conduct substantial manufacturing activities prior to introduction of the active pharmaceutical ingredient or finished drug product into interstate commerce.]
(b)(6)(6) [inserted: ]
[inserted: The Secretary shall issue regulations to implement subparagraphs (2) and (3) and may provide for reasonable variations in the implementation of, or an alternative placement for, the labeling requirements under such subparagraphs, including by electronic means. Such regulations shall take effect on a date determined by the Secretary and not earlier than 1 year after the date of publication of the final regulations, and shall apply with respect to drugs manufactured on or after the effective date of such regulations.]
(b)[struck: If in package form unless it bears a label containing (1) the name and place of business of the manufacturer, packer, or distributor; and (2) an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count: Provided, That under clause (2) of this paragraph reasonable variations shall be permitted, and exemptions as to small packages shall be established, by regulations prescribed by the Secretary.]
(c)(c) Prominence of information on label(c) Prominence of information on label
If any word, statement, or other information required by or under authority of this chapter to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.If any word, statement, or other information required by or under authority of this chapter to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.
(d)(d) Repealed. Pub. L. 105–115, title I, § 126(b), Nov. 21, 1997, 111 Stat. 2327(d) Repealed. Pub. L. 105–115, title I, § 126(b), Nov. 21, 1997, 111 Stat. 2327

Rest of § 352 unchanged

Step through the changes